Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Treatment of hyperinsulinemic hypoglycemia with GLP-1 antagonist exendin(9-39)

Treatment of hyperinsulinemic hypoglycemia with GLP-1 antagonist exendin(9-39)

US Patent 12220444 · Granted Feb 11, 2025

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Treatment of post-bariatric hypoglycemia with exendin (9-39)2024
Treatment of post-bariatric hypoglycemia with exendin (9-39)2024
Methods of using buffered formulations of exendin (9-39)2023
Methods of using buffered formulations of exendin (9-39)2023
Treatment of post-bariatric hypoglycemia with GLP-1 antagonists2023
Treatment of post-bariatric hypoglycemia with GLP-1 antagonists2023
Treatment of post-bariatric hypoglycemia with exendin (9-39)2023
Treatment of post-bariatric hypoglycemia with exendin (9-39)2023
Buffered formulations of exendin (9-39)2021
Buffered formulations of exendin (9-39)2021
Treatment of post-bariatric hypoglycemia with exendin (9-39)2021
Treatment of post-bariatric hypoglycemia with exendin (9-39)2021